Modulating the gut microbiome to improve immune checkpoint inhibitor efficacy

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, talks on the association of the gut microbiome with response to immunotherapies and modulating the gut microbiome to improve outcomes with immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.